Compare Medpace Holdings Inc (MEDP) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Uranium Energy Corp — how do they compare? Medpace Holdings Inc trades at $617.27 (market cap $16.82B), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Medpace Holdings Inc is far larger — about 3.7× Uranium Energy Corp's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Uranium Energy Corp for 37 Days on average.
| MEDP | UEC | |
|---|---|---|
Market Cap | $16.82B | $4.53B |
Volume | 223,093 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $630.19 | $20.14 |
52-Week Low | $393.42 | $9.04 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | $16.44B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
UEC trades at $9.24, down 2.43% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of -$87.66M in 2025, with revenue of $66.84M and a deeply negative net income margin of -368.62%. Recent news highlights operational expansion to two mines, but earnings misses in Q1 and Q2 2026 raise concerns about sustainability despite a Q4 beat.
Wall Street analysts remain bullish with an 87.5% buy rating and a $16.06 consensus price target, citing U.S. uranium demand growth. However, high cash burn, reliance on financing, and unproven production sustainability pose significant risks. The stock offers speculative upside if operational execution improves, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
